INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Encompass Health Corporation - EHC

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices by Encompass Health Corporation and its officers or directors [1] Group 1: Allegations and Impact - A New York Times article published on July 15, 2025, alleged that Encompass's for-profit hospitals perform below average on key safety measures, including having statistically significantly worse rates of potentially preventable readmissions at 34 facilities [3] - The article highlighted alarming mistakes that led to patient fatalities in Encompass-owned facilities [3] - Following the publication of the article, Encompass's stock price dropped by $12.39 per share, or 10.35%, closing at $107.28 per share on the same day [4] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [5]